HIV-1 infection

Active Ingredient: Tipranavir

Indication for Tipranavir

Population group: only adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Tipranavir, co-administered with low dose ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infection in highly pre-treated adults and adolescents 12 years of age or older with virus resistant to multiple protease inhibitors. Tipranavir should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options.

For this indication, competent medicine agencies globally authorize below treatments:

1000 mg in 2 divided doses daily

Route of admnistration


Defined daily dose

1,000 - 1,000 mg

Dosage regimen

From 500 To 500 mg 2 time(s) per day every day

Detailed description

The recommended dose of tipranavir is 500 mg, co-administered with 200 mg ritonavir (low dose ritonavir), twice daily.

Doses of ritonavir lower than 200 mg twice daily should not be used as they might alter the efficacy profile of the combination.

Since currently only limited efficacy and safety data are available for adolescents close monitoring of virologic response and tolerance is particularly warranted in this patient group.

Missed dose

Patients should be advised of the need to take tipranavir and ritonavir every day as prescribed. If a dose is missed by more than 5 hours, the patient should be instructed to wait and then to take the next dose of tipranavir and ritonavir at the regularly scheduled time. If a dose is missed by less than 5 hours, the patient should be instructed to take the missed dose immediately, and then to take the next dose of tipranavir and ritonavir at the regularly scheduled time.


Clinical studies of tipranavir did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, caution should be exercised in the administration and monitoring of tipranavir in older people reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other therapy.

Dosage considerations

It should be taken with food.

Active ingredient


Tipranavir is a non-peptidic inhibitor of the HIV-1 protease that inhibits viral replication by preventing the maturation of viral particles.

Read more about Tipranavir

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.